Clinical Infectious Disease: Changes in fibrosis 4 index can be used as a predictor of high risk of hepatocellular carcinoma after hepatitis C virus eradication

In chronic hepatitis C, almost all patients have achieved sustained virological response (SVR) through treatment with direct-acting antiviral drugs (DAA)
.

However, in some patients, hepatocellular carcinoma (HCC) can occur even after SVR, and strict follow-up is necessary for patients with a high risk of such occurrence

 In chronic hepatitis C, almost all patients have achieved sustained virological response (SVR) through treatment with direct-acting antiviral drugs (DAA)

 

A total of 3823 patients who received direct-acting antiviral therapy and obtained SVR were included in this study
.

FIB-4 was measured 24 weeks after the end of the direct-acting antiviral therapy and after the SVR reached (SVR24) and 1, 2 and 3 years after SVR24.

 

The results of the study found that in patients with FIB-4> 3.
25 at 1, 2 and 3 years after SVR24 and SVR24, the development of HCC was significantly higher than that of patients with FIB-4 ≤ 3.
25 at each point
.

The incidence of HCC at 1, 2, 3, and 4 years after SVR24 was significantly higher in patients with persistent FIB-4> 3.

 

This study confirms that the FIB-4 index can be used to assess the risk of HCC development at any time after SVR, and that changes in FIB-4 are related to changes in HCC development risks
.

Repeated evaluation of FIB-4 can be used as a prognostic indicator for high-risk HCC cohorts

This study confirms that the FIB-4 index can be used to assess the risk of HCC development at any time after SVR, and that changes in FIB-4 are related to changes in HCC development risks

 

Original source:

Nobuharu Tamaki.

Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Leave a message here